Form 4: Amgen VP Busch Sells Shares for Tax Obligations

Amgen's VP of Finance and CAO, Matthew C. Busch, disposed of 327 common shares at $366.21 each to cover tax liabilities.

Summary

• Matthew C. Busch, Amgen Inc.'s VP, Finance & CAO, reported a disposition of common stock.
• The transaction involved 327 shares of Amgen common stock.
• The shares were disposed of at a price of $366.21 per share.
• The transaction date was March 16, 2026.
• The disposition was made to the issuer (Amgen) to cover tax liability, indicated by transaction code 'F'.
• Following this transaction, Matthew C. Busch beneficially owns 4,048 shares of Amgen common stock.
• The shares beneficially owned include 68 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are credited to unvested Restricted Stock Units and paid out in shares upon vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents a routine, non-discretionary transaction by an executive to satisfy tax obligations related to vested equity, which is a common occurrence and does not reflect a change in company fundamentals or executive sentiment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that dispositions of shares to cover tax liabilities upon the vesting of equity awards are a standard and routine practice for executives. These transactions are typically pre-planned under Rule 10b5-1 plans and do not usually signal a change in management's outlook or confidence in the company's performance.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, tax-related transaction and not a discretionary sale indicating a change in executive confidence.

Key Dates

Recommendation

This Form 4 reports a routine disposition of shares by an executive to cover tax liabilities associated with vested equity. Such transactions are common and typically do not reflect a change in the executive's confidence in the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Amgen, AMGN, Insider Transaction, Form 4, Stock Sale, Executive Compensation, Tax Liability, Matthew C. Busch